Cargando…
Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women
A new HPV-16/18 bivalent vaccine expressed by the Escherichia coli has been proven to be efficacious in adult women. A randomized, immunogenicity noninferiority study of this candidate vaccine was conducted in December 2015 in China. Girls aged 9–14 years were randomized to receive 2 doses at months...
Autores principales: | Hu, Yue-Mei, Guo, Meng, Li, Chang-Gui, Chu, Kai, He, Wen-Gang, Zhang, Jing, Gu, Jian-Xiang, Li, Juan, Zhao, Hui, Wu, Xiang-Hong, Lin, BiZhen, Lin, Zhi-Jie, Yao, Xing-Mei, Li, Ya-Fei, Wei, FeiXue, Huang, Yue, Su, Ying-Ying, Zhu, Feng-Cai, Huang, Shou-Jie, Pan, Hui-Rong, Wu, Ting, Zhang, Jun, Xia, Ning-Shao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Science China Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223315/ https://www.ncbi.nlm.nih.gov/pubmed/31231780 http://dx.doi.org/10.1007/s11427-019-9547-7 |
Ejemplares similares
-
Cellular Immune Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent HPV Vaccine in Fijian Girls and Subsequent Responses to a Dose of Bivalent HPV Vaccine
por: Toh, Zheng Quan, et al.
Publicado: (2018) -
Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial
por: Mo, Zhao-Jun, et al.
Publicado: (2022) -
Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls
por: Yao, Xingmei, et al.
Publicado: (2022) -
Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial
por: Zhang, Xiao-Dong, et al.
Publicado: (2023) -
Split dosing of coronavirus disease 2019 vaccines provides noninferior antibody responsiveness to conventional vaccine dosing
por: Musa, Amal, et al.
Publicado: (2022)